Profile of Brentuximab Vedotin and Its Potential in the Treatment of Relapsed or Refractory Hodgkin Lymphoma
Blood and Lymphatic Cancer: Targets and Therapy
doi 10.2147/blctt.s21989
Full Text
Open PDFAbstract
Available in full text
Date
May 1, 2012
Authors
Publisher
Informa UK Limited